Loading...

TriSalus Life Sciences, Inc.

TLSINASDAQ
Healthcare
Medical - Devices
$4.56
$-0.11(-2.36%)

TriSalus Life Sciences, Inc. (TLSI) Company Profile & Overview

Explore TriSalus Life Sciences, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

TriSalus Life Sciences, Inc. (TLSI) Company Profile & Overview

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

SectorHealthcare
IndustryMedical - Devices
CEOMary T. Szela B.S.N.,

Contact Information

888 321 5212
6272 West 91st Avenue, Westminster, CO, 80031

Company Facts

110 Employees
IPO DateFeb 8, 2021
CountryUS
Actively Trading

Frequently Asked Questions

;